Upload File

onkologi-21-fin-apr-2017 · kuva 3 177lu-psma-617 at 24 hr 2nd 177lu-psma-617 at 24 hr 177...

  • Home
  • Documents
  • onkologi-21-fin-apr-2017 · Kuva 3 177Lu-PSMA-617 at 24 hr 2nd 177Lu-PSMA-617 at 24 hr 177 Esimerkki Lu-PSMA-617-hoitoannoskuvauksesta gammakameralla. Tällä potilaalla on verraten
5

Upload: others

Post on 24-Jan-2021

9 views

Category:

Documents


0 download

Report

TRANSCRIPT

Page 1: onkologi-21-fin-apr-2017 · Kuva 3 177Lu-PSMA-617 at 24 hr 2nd 177Lu-PSMA-617 at 24 hr 177 Esimerkki Lu-PSMA-617-hoitoannoskuvauksesta gammakameralla. Tällä potilaalla on verraten
Page 2: onkologi-21-fin-apr-2017 · Kuva 3 177Lu-PSMA-617 at 24 hr 2nd 177Lu-PSMA-617 at 24 hr 177 Esimerkki Lu-PSMA-617-hoitoannoskuvauksesta gammakameralla. Tällä potilaalla on verraten
Page 3: onkologi-21-fin-apr-2017 · Kuva 3 177Lu-PSMA-617 at 24 hr 2nd 177Lu-PSMA-617 at 24 hr 177 Esimerkki Lu-PSMA-617-hoitoannoskuvauksesta gammakameralla. Tällä potilaalla on verraten
Page 4: onkologi-21-fin-apr-2017 · Kuva 3 177Lu-PSMA-617 at 24 hr 2nd 177Lu-PSMA-617 at 24 hr 177 Esimerkki Lu-PSMA-617-hoitoannoskuvauksesta gammakameralla. Tällä potilaalla on verraten
Page 5: onkologi-21-fin-apr-2017 · Kuva 3 177Lu-PSMA-617 at 24 hr 2nd 177Lu-PSMA-617 at 24 hr 177 Esimerkki Lu-PSMA-617-hoitoannoskuvauksesta gammakameralla. Tällä potilaalla on verraten

PSMA Ligands for Radionuclide Imaging and Therapy of ... · agnostic imaging and therapy in patients with PCa with radiolabeled PSMA ligands is provided. Key words: PSMA, prostate

Production of 177Lu at the IFMIF-DONES Facility

Research Paper Lu]pentixather: Comprehensive Preclinical ...been paralleled by the use of [68Ga/177Lu]PSMA-I&T [34] 177and [68Ga/ Lu]PSMA-617 [35] for theranostics of metastatic castration

Production and chemical processing of 177Lu for nuclear ... · nuclear decay characteristics. Radiopharmaceuticals containing 177Lu are currently under development and tested for

68Ga- ja 177Lu-radiolääkkeiden laadunvalvontamenetelmien

PSMA - Power Sources Manufacturers Association

Directorio psma 2015

Geoscape · Geoscape Product Description Page 1 1. Overview 1.1 About PSMA – Delivery Organisation PSMA Australia Limited (PSMA) was formed by the governments of Australia in 1993

177Lu-labelled macrocyclic bisphosphonates for targeting

PRODUCTION AND QUALITY CONTROL OF 177Lu-DOTATATE …

The 68Ga/177Lu theragnostic concept in PSMA targeting of ...68Ga-PSMA-HBED-CC PET/CT imaging and SUV max analysis 68Ga-PSMA-HBED-CC PET/CT imaging was performed using a dedicated PET/CT

Theranostics Targeted Radionuclide Therapy with A 177Lu-labeled

Dosimetry of 177Lu-PSMA-617 in Metastatic Castration ...jnm.snmjournals.org/content/60/4/517.full.pdf · Dosimetry of 177Lu-PSMA-617 in Metastatic Castration- Resistant Prostate Cancer:

Maintainingradiochemicalpurityof [177Lu]Lu‑DOTA‑PSMA‑617 ... · 288 Journal of Radioanalytical and Nuclear Chemistry (2019) 321:285–291 1 3 Results Deeminaionofeecieneofenche

PSMA-Programa Semana Santa 2015

68Ga-PSMA-PET/CT for the evaluation of liver metastases in ......ADT 11 (84.6) CTX 7 (53.8) 177Lu-PSMA 4 (30.8) RP Radical prostatectomy, RT Radiotherapy, ADT Androgen deprivation

PSMA pet ct scan

Psb-psma Ikhlas berbagi rela memberi. psb-psma Rela berbagi ikhlas memberi

The 68Ga/177Lu-theragnostic concept in PSMA-targeting of … · 2020-02-06 · PSA serum levels. 68Ga-PSMA-11 PET/CT revealed a higher ... Preparation of radio-labeled PSMA-targeting

Social networking for lawyers psma

ATACs fighting Cancer...2019/11/25  · PSMA -ATAC – Prostate Cancer – Next Potential ATAC Development Candidate • PSMA is a clinically validated target, e.g. 177Lu -PSMA -617,

GA PSMA PET_EN

Presentacion oct2015 psma

Padronizacao Absoluta Do 177lu e Do 111in

 · Web viewAnalysis of PSMA Expression and Outcome in Patients with advanced Prostate Cancer receiving 177Lu-PSMA-617 Radioligand Therapy . Robert Seifert1,2,3,4, Konstantin Seitzer1,4,5,

177Lu – DOTA0 – Tyr3] – OCTREOTATE PARA EL TRATAMIENTO …

PSMA Targeted Therapies...Up to 4 cycles 177Lu-PSMA 50 included in analysis Peter Mac Phase II Baseline characteristics & schema Characteristic Median or N (%) Age (years) 71 Alkaline

Original Article Synthesis and evaluation of [ Cu]PSMA-617 ...Synthesis and evaluation of [64Cu]PSMA-617 targeted for prostate-specific membrane antigen in prostate cancer Can Cui1*,

177Lu-PSMA targeted Radionuclide Therapy€¦ · Gaertner et al. Uptake of PSMA-ligands in normal tissues is dependent on tumor load in patients with prostate cancer. Oncotarget,

Evaluation of safety and dosimetry of 177Lu-DOTA-ZOL for ...2021/01/08  · Ga-PSMA-11 (n=2) or 18 F-PSMA-66 1007 (n=7) PET/CT scans within one week prior to therapy. Blood biomarkers

Chemistry and bifunctional chelating agents for binding 177Lu

Betalutin (177Lu-Lilotomab) - Studio ER Congressi ... · Betalutin (177Lu-Lilotomab) Arne Kolstad Oslo University Hospital Norway May 10, 2016 . ... • Firenze - Prof. Bosi •Poland

Transcriptional effects of 177Lu-octreotate therapy using ... · ORIGINAL RESEARCH Open Access Transcriptional effects of 177Lu-octreotate therapy using a priming treatment schedule

The Intratumoral Distribution of Radiolabeled 177Lu … · Intratumoral Distribution of Radiolabeled 177Lu-BR96 Monoclonal Antibodies ... The Intratumoral Distribution of Radiolabeled

177Lu-DOTA-octreotate Radionuclide Therapy of ...562732/FULLTEXT01.pdfGarske-Román, U. 2012. 177Lu-DOTA-octreotate Radionuclide Therapy of Neuroendocrine Tumours: Dosimetry-Based